DE69221605D1 - Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) - Google Patents

Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Info

Publication number
DE69221605D1
DE69221605D1 DE69221605T DE69221605T DE69221605D1 DE 69221605 D1 DE69221605 D1 DE 69221605D1 DE 69221605 T DE69221605 T DE 69221605T DE 69221605 T DE69221605 T DE 69221605T DE 69221605 D1 DE69221605 D1 DE 69221605D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
iddm
diabetes mellitus
dependent diabetes
specific monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69221605T
Other languages
English (en)
Other versions
DE69221605T2 (de
Inventor
Anne Cooke
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of DE69221605D1 publication Critical patent/DE69221605D1/de
Application granted granted Critical
Publication of DE69221605T2 publication Critical patent/DE69221605T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69221605T 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) Expired - Lifetime DE69221605T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100741A GB9100741D0 (en) 1991-01-14 1991-01-14 Treatment of disease
PCT/GB1992/000074 WO1992011869A1 (en) 1991-01-14 1992-01-14 Non-depleting cd4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (iddm)

Publications (2)

Publication Number Publication Date
DE69221605D1 true DE69221605D1 (de) 1997-09-18
DE69221605T2 DE69221605T2 (de) 1998-02-12

Family

ID=10688399

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69221605T Expired - Lifetime DE69221605T2 (de) 1991-01-14 1992-01-14 Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)

Country Status (10)

Country Link
US (1) US5670150A (de)
EP (1) EP0567490B1 (de)
JP (1) JP3168005B2 (de)
AT (1) ATE156711T1 (de)
AU (1) AU668081B2 (de)
CA (1) CA2100462C (de)
DE (1) DE69221605T2 (de)
ES (1) ES2106169T3 (de)
GB (1) GB9100741D0 (de)
WO (1) WO1992011869A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001510A4 (de) * 2006-03-16 2010-06-09 Genentech Inc Verfahren zur behandlung von lupus mit cd4-antikörpern
WO2010009129A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Methods of treating autoimmune diseases using cd4 antibodies
EP3019193B1 (de) * 2013-07-10 2019-09-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Durch apoptotische zellen vermittelte einleitung antigenspezifischer regulatorischer t-zellen zur therapie von autoimmunkrankheiten bei tieren und menschen
US20210169930A1 (en) * 2018-04-17 2021-06-10 National Cancer Center Anticancer t cell therapy product-assisting composition comprising depleting anti-cd4 monoclonal antibody and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008278A1 (en) * 1989-01-23 1990-07-23 Herve Bazin Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies

Also Published As

Publication number Publication date
EP0567490A1 (de) 1993-11-03
JP3168005B2 (ja) 2001-05-21
US5670150A (en) 1997-09-23
CA2100462C (en) 2003-06-17
DE69221605T2 (de) 1998-02-12
GB9100741D0 (en) 1991-02-27
WO1992011869A1 (en) 1992-07-23
ATE156711T1 (de) 1997-08-15
CA2100462A1 (en) 1992-07-15
JPH06504283A (ja) 1994-05-19
EP0567490B1 (de) 1997-08-13
ES2106169T3 (es) 1997-11-01
AU668081B2 (en) 1996-04-26
AU1164792A (en) 1992-08-17

Similar Documents

Publication Publication Date Title
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DK0617575T3 (da) Indretning til dyrkning af planter
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
PT724456E (pt) Anticorpos contra cd4
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE69102552D1 (de) Verfahren zur Behandlung von Fasermaterialien.
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
FI98510B (fi) Vateriitti ja menetelmä sen valmistamiseksi
DE3162128D1 (en) Biologically active compounds, their obtention from human casein and compositions containing them
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE69221725D1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE71149T1 (de) Monoklonale antikoerper.
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition